Background illustration for clinical trials search

Vaccines Clinical Trials

Find clinical trials for vaccines. Search for vaccines clinical trials in different cities and states across the United States.

Filter

Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

for
HPV-Related Squamous Cell Carcinoma
Location: Baltimore MD
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sex: All

Age: 18+

Code: NCT04988074

Phase 2, Recruiting

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

for
High Grade Epithelial Ovarian Cancer,
Location: Boston MA, Providence RI, Camden NJ, Doylestown PA,
Sponsor: Genmab

Sex: All

Age: 18+

Code: NCT05579366

Phase 1, Phase 2, Recruiting

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

for
Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer,
Location: New Brunswick NJ, Bethesda MD
Sponsor: Christian Hinrichs

Sex: All

Age: 18+

Code: NCT05686226

Phase 2, Recruiting

PRE-ISPY Phase I/II Oncology Platform Program

for
HER2-positive Breast Cancer, Metastatic Cancer,
Location: Birmingham AL, Chicago IL, Orland Park IL, New Lenox IL,
Sponsor: QuantumLeap Healthcare Collaborative

Sex: All

Age: 18+

Code: NCT05868226

Phase 1, Phase 2, Recruiting

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

for
HPV-Related Cervical Carcinoma,
Location: Orlando FL, Tampa FL, Tulsa OK
Sponsor: Theravectys S.A.

Sex: All

Age: 18+

Code: NCT06319963

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

for
Sarcoma, HER-2 Protein Overexpression, Osteosarcoma,
Location: Houston TX
Sponsor: Baylor College of Medicine

Sex: All

Age: 1 - 25

Code: NCT04995003

Phase 1, Recruiting

Oropharynx (OPX) Biomarker Trial

for
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06356272

Recruiting

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

for
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma,
Location: New Brunswick NJ
Sponsor: Christian Hinrichs

Sex: All

Age: 18+

Code: NCT05639972

Phase 1, Phase 2, Recruiting

Alcohol and Sexual Communication Among Couples in the Laboratory

for
Alcohol Intoxication, Intimate Partner Violence (IPV),
Location: Aurora CO
Sponsor: University of Colorado, Denver

Sex: All

Age: 21 - 65

Code: NCT06865872

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

for
Locally Advanced or Metastatic ER+ HER2- Breast Cancer,
Location: New Haven CT, Edgewood KY, Louisville KY, Nashville TN,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT04606446

Phase 2, Recruiting

Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer

for
Cancer of the Head and Neck, Oropharynx Cancer,
Location: Columbia MO
Sponsor: University of Missouri-Columbia

Sex: All

Age: 18+

Code: NCT04444869

Phase 2, Recruiting

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Boston MA, Rochester NY, Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 65+

Code: NCT06042569

Phase 2, Recruiting

Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

for
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Location: St Louis MO, Worthington MN, Fargo ND, Sioux Falls SD
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT04966481

Phase 3, Recruiting

TRUDI: TDXD+Durva in HER2+/Low IBC

for
Invasive Breast Cancer, Inflammatory Breast Cancer Stage III,
Location: Boston MA, Houston TX
Sponsor: Filipa Lynce, MD

Sex: Female

Age: 18+

Code: NCT05795101

Phase 2, Recruiting

The Role of Dentists in Human Papillomavirus Vaccination

for
HPV
Location: Winterville NC
Sponsor: East Carolina University

Sex: All

Age: 18 - 70+

Code: NCT04757701

Recruiting

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

for
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma,
Location: Baltimore MD
Sponsor: University of Maryland, Baltimore

Sex: All

Age: 18+

Code: NCT06088381

Phase 2, Recruiting

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

for
Anatomic Stage IV Breast Cancer AJCC v8,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 18+

Code: NCT05098210

Phase 1, Recruiting

Role of the Immune Environment in Response to Therapy in Breast Cancer

for
Breast Cancer, ER Positive Breast Cancer,
Location: Philadelphia PA
Sponsor: Abramson Cancer Center at Penn Medicine

Sex: Female

Age: 18+

Code: NCT05396612

Recruiting

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Atlanta GA
Sponsor: Emory University

Sex: Female

Age: 18+

Code: NCT05464810

Early Phase 1, Recruiting

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

for
HPV, Throat Cancer, Oropharyngeal Carcinoma,
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT05491512

Phase 2, Recruiting

What vaccine clinical trials are studying now

New flu vaccines. Moderna's mFlusiva, approved August 5, 2026 for adults 50 and older, is the first mRNA flu vaccine. In its Phase 3 trial it prevented about 27 percent more flu cases than a standard dose vaccine, with more short term side effects. Flu vaccine studies, including human challenge trials, are listed on our influenza clinical trials page.

Vaccines in pregnancy. Vaccinating a mother so antibodies pass to the baby is one of the most active areas of research. A Phase 3 trial of a group B streptococcus vaccine, a leading cause of serious infection in newborns, is recruiting pregnant participants at 120 US sites.

Pneumococcal and other bacterial vaccines. Next generation vaccines that cover more strains of the bacteria behind pneumonia and meningitis, tested against the vaccines in use today. Two pneumococcal vaccine studies are enrolling healthy adults 18 to 75 who have never had a pneumococcal vaccine.

RSV vaccines. Combination and revaccination studies, covered on our RSV vaccine clinical trials page. Studies of new flu and RSV vaccines for adults 60 and older are enrolling now.

Cancer vaccines. These do not prevent cancer; they teach the immune system to attack a cancer that is already there. Intismeran, made for each patient from up to 34 mutations in their own tumor, met its main goal in a Phase 3 melanoma trial in August 2026 but is not yet approved. Smaller studies test vaccines for HER2 positive breast cancer, liver cancer, and HPV related cancers; see our melanoma and breast cancer pages.

COVID-19. Updated formulas are approved each season; the 2026 to 2027 mRNA formula is approved for adults 65 and older and for people 5 to 64 with a condition that raises their risk. One study is testing a COVID-19 vaccine given during an active infection, for people 12 and older who tested positive within the past 5 days and have a risk factor for severe illness; it measures the immune response and is not a treatment for the current illness. Studies of COVID-19 and long COVID are on our COVID-19 page.

Vaccines for infections that have none yet. There is still no approved vaccine against Epstein-Barr virus, the cause of mono, or against C. difficile, a common hospital infection. A study of an EBV vaccine is enrolling healthy adults 18 to 30, and C. diff vaccine studies are enrolling adults 65 and older who have frequent contact with healthcare but have never had the infection.

Human challenge studies. Healthy adults receive a vaccine or placebo, then a controlled dose of a virus such as influenza, in a monitored setting. They answer in weeks what field trials take seasons to show.

Article preview image

65 or older? Read our guide: Not All Flu Vaccines Work the Same After 65: Which to Choose and When to Get It

Not All Flu Vaccines Work the Same After 65: Which to Choose and When to Get It

How vaccine trials differ from drug trials

Who can participate in vaccine clinical trials?

Do vaccine trial participants get paid?

How to enroll in a vaccine clinical trial